Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (Nasdaq: CLDI) is a clinical-stage biotherapeutics company focused on engineered cell-based platforms that pair stem cells with oncolytic viruses to treat solid tumors across multiple cancer indications. The company reached public markets through a de-SPAC merger with First Light Acquisition Group, a blank-check company sponsored by First Light Acquisition Group LLC that completed its IPO in 2021 targeting the healthcare and life sciences sector. The business combination closed in September 2023, with the combined entity trading on Nasdaq under the CLDI ticker. This 10-Q quarterly report was filed with the SEC on August 10, 2022, capturing the company's financial position during the pre-merger period. For full filing analytics, deal timelines, and SPAC intelligence on CLDI and the broader market, sign up for complete data access at SpacDesk.